Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 29.

Journal Article

Buelow, L., Keupp, K., Richters, L., Pohl, E., Wappenschmidt, B., Zarghooni, V., Reichstein-Gnielinski, S., Maringa, M., Giesecke, J., Rhiem, K., Hahnen, E. and Schmutzler, R. (2017). Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation - The origin of a constitutional mutation in a breast cancer family. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Danner, M., Mueller, D., Schmutzler, R., Rhiem, K., Engel, C., Stollenwerk, B., Stock, S. and Wassermann, K. (2016). ECONOMIC MODELING OF RISK-ADAPTED SCREEN-AND-TREAT STRATEGIES IN WOMEN AT HIGH-RISK FOR BREAST OR OVARIAN CANCER. Value Health, 19 (7). S. A737 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1524-4733

Dick, J., Rhiem, K., Bredart, A., Stock, S. and Schmutzler, R. K. (2018). An international multicenter cross-sectional prospective study in improving psychosocial care for women with breast cancer risk after diagnostic gene sequencing (BRIDGES). Oncol. Res. Treat., 41. S. 35 - 37. BASEL: KARGER. ISSN 2296-5262

Dick, J., Rhiem, K., Herold, N., Huebbel, A., Huebbel, V., Bredow, K., Giesecke, J., Reichstein-Gnielinski, S., Maringa, M., Scheer, N. and Schmutzler, R. K. (2018). Influence factors on the preference for preventive strategies in healthy BRCA1/2 Mutation carriers. Oncol. Res. Treat., 41. S. 37 - 38. BASEL: KARGER. ISSN 2296-5262

Dick, J., Rhiem, K., Mensah, J., Wesselmann, S. and Schmutzle, R. K. (2018). Survey on physicians' training needs in counselling of persons with familial breast and ovarian cancer risk. Oncol. Res. Treat., 41. S. 36 - 37. BASEL: KARGER. ISSN 2296-5262

Dukatz, R., Halle, M., Engel, C., Berling, A., Hebestreit, K., Bischoff, S., Pfeifer, K., Grill, S., Yahiaoui-Doktor, M., Enders, U., Siniatchkin, M., Gerber, D., Bridstrup, J., Erickson, N., Loeffler, M., Meindl, A., Rhiem, K., Schmutzler, R. and Kiechle, M. (2016). Feasibility assessment on a lifestyle intervention in healthy and diseased BRCA 1/2 mutation carriers. Oncol. Res. Treat., 39. S. 59 - 60. BASEL: KARGER. ISSN 2296-5262

Herold, N., Bredow, K., Hahnen, E., Wappenschmidt, B., Hauke, J., Wiedemann, R., Waha, A., Bluemcke, B., Pohl-Rescigno, E., Portnicki, M., Rhiem, K. and Schmutzler, R. (2020). Implementation of an educational program and risk-adjusted prevention program for breast and ovarian cancer of the German Consortium for Hereditary Breast- and Ovarian Cancer. Geburtshilfe Frauenheilkd., 80 (6). S. E37 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Herold, N., Bredow, K., Hahnen, E., Wappenschmidt, B., Hauke, J., Wiedemann, R., Waha, A., Bluemcke, B., Portnicki, M., Pohl-Rescigno, E., Rhiem, K., Kast, K., Huebbel, V, Maringa, M., Crombach, G. and Schmutzler, R. (2020). Knowledge-generating Care using the Example of hereditary Breast- and Ovarian Cancer (BC/OC): Evaluation of the comprehensive Care Concept. Geburtshilfe Frauenheilkd., 80 (10). S. E212 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Herold, N., Lichenheldt, F., Hillebrand, V., Wappenschmidt, B., Hahnen, E., Rhiem, K. and Schmutzler, R. K. (2018). Evaluation of prophylactic mastectomy and breast reconstruction in female BRCA1/2 mutation carriers. Oncol. Res. Treat., 41. S. 41 - 42. BASEL: KARGER. ISSN 2296-5262

Isselhard, A., Toepper, M., Berger-Hoeger, B., Steckelberg, A., Fischer, H., Vitinius, F., Beifus, K., Koeberlein-Neu, J., Wiedemann, R., Rhiem, K., Schmutzler, R. and Stock, S. (2020). Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study. Trials, 21 (1). LONDON: BMC. ISSN 1745-6215

Keupp, K., Ernst, C., Bluemcke, B., Versmold, B., Waha, A., Driesen, J., Baasner, A., Larsen, M., Buelow, L., Kroeber, S., Altmueller, J., Thiele, H., Nuernberg, P., Wappenschmidt, B., Neidhardt, G., Rhiem, K., Schmutzler, R., Hahnen, E. and Hauke, J. (2018). Next-generation sequencing via TruRisk (R) genepanel reveal high mutation prevalence in additional risk genes in German BRCA1/2-negative breast and ovarian cancer families. Eur. J. Hum. Genet., 26. S. 541 - 543. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438

Keupp, K., Richters, L., Buelow, L., Kroeber, S., Ernst, C., Bluemcke, B., Versmold, B., Waha, A., Driesen, J., Baasner, A., Altmueller, J., Thiele, H., Nuernberg, P., Wappenschmidt, B., Neidhardt, G., Rhiem, K., Schmutzler, R., Hahnen, E. and Hauke, J. (2017). TruRisk (R) based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B., V, Blohmer, J-U, Grischke, E-M, Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C. and Schneeweiss, A. (2019). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol., 30 (8). S. 1279 - 1289. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C. T., Rezai, M., Blohmer, J. U., Zahm, D. M., Jackisch, C., Gerber, B., Klare, P., Kuemmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A-R, von Minckwitz, G. and Untch, M. (2018). Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann. Oncol., 29 (12). S. 2341 - 2348. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Neidhardt, G., Hauke, J., Heilmann, S., Hellebrand, H., Surowy, H. M., Klaschik, K., Honisch, E., Gehrig, A., Sutter, C., Rump, A., Bogdanova-Markov, N., Bugert, P., Mangold, E., Steinemann, D., Ramirez, A., Ditsch, N., Arnold, N., Niederacher, D., Burwinkel, B., Thiele, H., Altmueller, I., Nuernberg, P., Engel, C., Wappenschmidt, B., Rhiem, K., Meindl, A., Schmutzler, R. K. and Hahnen, E. (2016). Compelling evidence for FANCM as a breast cancer susceptibility gene. Oncol. Res. Treat., 39. S. 54 - 55. BASEL: KARGER. ISSN 2296-5262

Pohl, E., Schneeweiss, A., Hauke, J., Moebus, V., Furlanetto, J., Denkert, C., Fasching, P. A., Hanusch, C., Tesch, H., Weber-Lassalle, N., Mueller, V., Rhiem, K., Untch, M., Luebbe, K., Lederer, B., Jackisch, C., Nekljudova, V., Schmutzler, R. K., Hahnen, E. and Loibl, S. (2018). Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Rhiem, K., Bick, U., Kast, K., Niederacher, D., Solbach, C., Emons, G., Witzel, I., Brigitte, S., Bartram, C., Maass, N., Lemke, J., Kiechle, M., Mahner, S., Wieacker, P., Ortmann, O., Riess, O., Janni, W., Haaf, T. and Schmutzler, R. K. (2018). New structures of the German Consortium for Hereditary Breast and Ovarian Cancer. Oncol. Res. Treat., 41. S. 183 - 184. BASEL: KARGER. ISSN 2296-5262

Rhiem, K., Herold, N., Bongartz, R., Schellong, G. and Schmutzler, R. (2014). Breast Cancer in young women after radiation therapy of Hodgkin disease in childhood and adolescence - individual therapeutic strategies. Oncol. Res. Treat., 37. S. 21 - 22. BASEL: KARGER. ISSN 2296-5262

Rhiem, K., Richters, L., Hahnen, E., Lampe, B., Rezai, M., Goehring, U. -J., Schumacher, C., Kuemmel, S., Ataseven, B. and Schmutzler, R. (2016). Benchmarking of the DKG check list for inclusion criteria of BRCA testing. Oncol. Res. Treat., 39. S. 59 - 60. BASEL: KARGER. ISSN 2296-5262

Rhiem, K. and Schmutzler, R. K. (2018). Comprehensive care for families with hereditary breast and ovarian cancer. Gynakologe, 51 (5). S. 403 - 409. CHAM: SPRINGER INTERNATIONAL PUBLISHING AG. ISSN 1433-0393

Rhiem, K. and Schmutzler, R. K. (2015). Risk factors and prevention of breast cancer. Onkologe, 21 (3). S. 202 - 211. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Rhiem, K. and Schmutzler, R. K. (2015). Risk factors and prevention of breast cancer. Onkologe, 21 (3). S. 202 - 211. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Rhiem, K. and Schmutzler, R. K. (2014). Risk-adapted surveillance. Focus on familial breast and ovarian cancer. Bundesgesundheitsblatt-Gesund., 57 (3). S. 307 - 312. NEW YORK: SPRINGER. ISSN 1437-1588

Rhiem, K., Schott, S., Tio, J., Speiser, D., Briest, S., Vesper, A. -S., Kast, K., Kiechle, M., Wockel, A., Mundhenke, C., Ditsch, N., Janni, W., Seitz, S. and Schmutzler, R. K. (2018). Results of intensified breast cancer Screening in women after Radiation for Hodgkin's lymphoma in childhood and adolescence. Oncol. Res. Treat., 41. S. 7 - 8. BASEL: KARGER. ISSN 2296-5262

Rhiem, K., Wesselmann, S., Mensah, J., Bick, U., Blohmer, J. -U., du Bois, A., Emons, G., Gaissmaier, W., Hahne, A., Koch, K., Meindl, A., Scharl, A. J., Brigitte, S. and Schmutzler, R. K. (2018). Education Program of the German Consortium for Hereditary Breast and Ovarian Cancer and the German Cancer Sociey to improve genetic literacy and trans-sectoral cooperation in the Genome era. Oncol. Res. Treat., 41. S. 183 - 184. BASEL: KARGER. ISSN 2296-5262

Richters, L., Rhiem, K., Wappenschmidt, B., Kiechle, M. and Schmutzler, R. (2014). Pathological complete response rates in patients with BRCA1/2-associated breast cancer after neoadjuvant chemotherapy. Oncol. Res. Treat., 37. S. 13 - 15. BASEL: KARGER. ISSN 2296-5262

Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kuemmel, S., Rhiem, K., Warm, M., Fasching, P. A., Just, M., Hanusch, C., Hackmann, J., Blohmer, J-U., Furlanetto, J., Nekljudova, V., von Minckwitz, G. and Loibl, S. (2018). Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). Ann. Oncol., 29. S. 60 - 61. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Waha, A., Versmold, B., Kast, K., Kiechle, M., Ditsch, N., Meindl, A., Niederacher, D., Hahnen, E., Arnold, N., Mundhenke, C., Horvath, J., Bernd, A., Dikow, N., Hauke, J., Wappenschmidt, B., Riess, O., Schott, S., Speiser, D., Faust, U., Sutter, C., Rhiem, K. and Schmutzler, R. K. (2018). Consensus recommendation of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) on the transfer of multigene analysis data into the clinical care program. Oncol. Res. Treat., 41. S. 182 - 183. BASEL: KARGER. ISSN 2296-5262

Wassermann, K., Rhiem, K. and Schmutzler, R. (2014). Psychosocial Factors Relating to the Decision Against or in Favour for Prophylactic Surgery. Oncol. Res. Treat., 37. S. 111 - 112. BASEL: KARGER. ISSN 2296-5262

This list was generated on Thu Oct 21 05:38:49 2021 CEST.